- PharmaLogic has supplied the first cohort dosing of Ratio Therapeutics’ investigational radiopharmaceutical, [Ac-225]-RTX-2358, for the ATLAS trial.
- The dose was manufactured and delivered from PharmaLogic’s radiopharmaceutical facility in the Bronx, New York.
PharmaLogic Holdings Corp. has announced that it has successfully supplied the first cohort dosing of Ratio Therapeutics’ investigational FAP-targeted radiopharmaceutical, [Ac-225]-RTX-2358, for the ATLAS clinical trial. The company operates as a contract development and manufacturing organisation (CDMO) focused on radiopharmaceuticals and provides contract manufacturing services for clinical and commercial programmes.
The dose was manufactured and delivered from PharmaLogic’s radiopharmaceutical manufacturing facility in the Bronx, New York. The site supports both clinical and commercial supply for advanced radiopharmaceutical programmes.
“The supply of the first cohort doses from our Bronx facility underscores our commitment to supporting the development of and access to innovative radiopharmaceutical therapies around the globe.”
Etienne Montagut, President and CEO of PharmaLogic
PharmaLogic said the collaboration with Ratio Therapeutics reflects its role in supporting radiopharmaceutical development through CDMO and contract manufacturing services, including manufacturing and delivery for clinical trials.
